Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Vertex Pharmaceuticals
VRTXHealthcareGenerated Aug 19, 2026, 11:14 PM UTC
VRTX (Vertex Pharmaceuticals) analytical snapshot. Revenue grew +8.9% YoY to $12.00B. 5-year revenue CAGR +9.6%; 10y CAGR +24.2%. Net margin at 32.94% (contracting ▼). Market cap $139.93B at $552.06 per share. Trailing P/E 36.04, P/S 11.66, P/B 6.91. EV/Operating income ≈ 32.08 (EV $133.89B). Risk: Low. Macro: Risk-on · Supportive. Composite analytical score -2 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest quarterly report (10-Q) filed Aug 4, 2026. 6 recent 8-K material-event filings in the index. Recent insider Form 4s: 0 buy vs 0 sell transactions.
- Latest quarterly report (10-Q) filed Aug 4, 2026.
- 6 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- 6 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 14 recent 13G passive institutional ownership notices.
| Date | Form | Description |
|---|---|---|
| Aug 3, 2026 | 8-K | 8-K |
| Jul 7, 2026 | 8-K | 8-K |
| May 13, 2026 | 8-K | 8-K |
| May 4, 2026 | 8-K | 8-K |
| Apr 29, 2026 | 8-K | 8-K |
| Mar 31, 2026 | 8-K | 8-K |
SEC Filing Deep-Analysis
6 risk signal(s), 1 watch item(s) detected from XBRL filing diff analysis. Revenue grew +8.9% but receivables grew +27.6% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
- Receivables outpacing revenue: Accounts receivable grew +27.6% YoY vs revenue growth of +8.9%. The +18.6% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
- Inventory buildup exceeds sales growth: Inventory grew +39.9% vs revenue +8.9%. Excess inventory may signal weakening demand, potential write-downs, or supply chain overcommitment. Watch gross margin for discounting impact.
- NEW: Going concern doubt in latest filing: The term "going concern" "substantial doubt" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
- Material weakness in internal controls: The term "material weakness" "internal control" appears in 2 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Substantial doubt about ability to continue in latest filing: The term "substantial doubt" "ability to continue" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 3 filing(s).
- Restatement of financial statements: The term "restatement of" "previously issued" appears in 5 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- Endogenous analysis: Revenue grew +8.9% but receivables grew +27.6% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
- 10 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 3 new risk-language term(s) detected in filing text: Going concern doubt, Substantial doubt about ability to continue, Off-balance sheet arrangements.
- Ongoing high-severity risk language: Material weakness in internal controls, Restatement of financial statements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $11.02B | $12.00B | $981.2M | +8.9% |
| Operating income | $-232.9M | $4.17B | $4.41B | +1891.9% |
| Net income | $-535.6M | $3.95B | $4.49B | +838.1% |
| Operating cash flow | $-492.6M | $3.63B | $4.12B | +837.2% |
| Capex | $297.7M | $437.6M | $139.9M | +47.0% |
| Total assets | $22.53B | $25.64B | $3.11B | +13.8% |
| Total liabilities | $6.12B | $6.98B | $853.6M | +13.9% |
| Cash & equivalents | $4.57B | $5.08B | $515.2M | +11.3% |
| Stockholders equity | $16.41B | $18.67B | $2.26B | +13.7% |
| Inventory | $1.21B | $1.69B | $481.4M | +39.9% |
| Accounts receivable | $1.61B | $2.05B | $443.4M | +27.6% |
| R&D expense | $1.83B | $3.05B | $1.22B | +66.8% |
| SG&A expense | $1.46B | $1.75B | $288.8M | +19.7% |
| Interest expense | $58.5M | $58.2M | $-351000 | -0.6% |
| Type | Concepts |
|---|---|
| Added | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax, AvailableForSaleDebtSecuritiesAmortizedCostBasis, AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue, AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue, AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue, AvailableForSaleSecuritiesDebtSecurities, EquitySecuritiesWithoutReadilyDeterminableFairValueAmount, InvestmentIncomeNet, ProceedsFromCollectionOfNotesReceivable, RealizedInvestmentGainsLosses |
| Removed | AccruedRoyaltiesCurrent, AdvertisingExpense, AmortizationOfIntangibleAssets, BusinessCombinationContingentConsiderationLiabilityNoncurrent, CapitalizedComputerSoftwareAmortization1, CapitalizedComputerSoftwareGross, CashFlowHedgeDerivativeInstrumentAssetsAtFairValue, ContractWithCustomerLiabilityRevenueRecognized, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 3 | 0 | NEW |
| Material weakness in internal controls | high | 2 | 2 | Ongoing |
| Substantial doubt about ability to continue | high | 3 | 0 | NEW |
| Restatement of financial statements | high | 5 | 2 | Ongoing |
| Impairment charge | medium | 5 | 5 | Ongoing |
| Restructuring | medium | 5 | 2 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 0 | NEW |
| Related party transactions | low | 5 | 1 | Ongoing |
Fundamentals
Revenue grew +8.9% YoY to $12.00B. 5-year revenue CAGR +9.6%; 10y CAGR +24.2%. Net margin at 32.94% (contracting ▼).
- Revenue grew +8.9% YoY to $12.00B.
- 5-year revenue CAGR +9.6%; 10y CAGR +24.2%.
- Net margin at 32.94% (contracting ▼).
- Return on equity 21.18%, ROA 15.42%, ROIC 22.36%.
- Gross margin 0.00%, operating margin 34.77%.
- Free cash flow margin 26.61% ($3.19B).
- Net income up ▲ +838.1% YoY.
- Debt/equity 0.01, current ratio 3.19, net debt -$6.04B.
- Asset turnover 0.44 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $11.02B | +11.7% | 0.00 | -2.11 | -4.86 | -$790.3M | -3.26 |
| 2025 | $12.00B | +8.9% | 0.00 | 34.77 | 32.94 | $3.19B | 21.18 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Jun 30, 2016 | $431.6M | +159.9% | — | -14.95% |
| Sep 30, 2016 | $413.8M | +33.6% | -4.1% | -9.39% |
| Mar 31, 2017 | $714.7M | +79.5% | +72.7% | 34.66% |
| Jun 30, 2017 | $544.1M | +26.1% | -23.9% | 3.31% |
| Sep 30, 2017 | $578.2M | +39.7% | +6.3% | -17.81% |
| Mar 31, 2018 | $640.8M | -10.3% | +10.8% | 32.81% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $139.93B at $552.06 per share. Trailing P/E 36.04, P/S 11.66, P/B 6.91. EV/Operating income ≈ 32.08 (EV $133.89B).
- Market cap $139.93B at $552.06 per share.
Price & Technicals
Price $552.06 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 74.82 (overbought).
- Price $552.06 — uptrend (above 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Low. Leverage debt/equity 0.01 (low). Liquidity current ratio 3.19 (adequate).
- Composite risk: Low.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite -2
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Vertex Pharmaceuticals is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewRevenue grew **+8.9%** YoY to $12.00B..
Peer comparison
Defensive groupHow VRTX stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 19 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Gilead Sciences GILD | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX● you | -2 | Neutral |
| AbbVie Inc. ABBV | -5 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Kroger Co. KR | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Walmart Inc. WMT | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |